Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient - Reuters UK

6:26am PDT - June 29th, 2020    remdesivir - Reuters

Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $2,340 (1,901 pounds) for a five-day treatment in the United States and some other developed countries, it said on Monday, as it set the price for a single vial at $390.